Related Experiment Video
Updated: Jun 18, 2026
07:07
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Randomized clinical trials in melanoma.
T Peter Kingham1, Giorgos Karakousis, Charlotte Ariyan
1Department of Surgery, Memorial Sloan-Kettering Cancer Center, NY, NY, USA. kinghamt@mskcc.org
Surgical Oncology Clinics of North America
|November 17, 2009
Summary
Melanoma incidence is rising, with a 1 in 55 lifetime risk in the US. This review details key randomized controlled trials (RCTs) from 2001-2008, building on earlier research to refine melanoma treatment.
Area of Science:
- Oncology
- Dermatology
- Clinical Trials
Background:
- The incidence of malignant melanoma is increasing globally.
- Lifetime risk of melanoma in the United States is estimated at 1 in 55.
- Numerous randomized trials have advanced melanoma treatment strategies.
Purpose of the Study:
- To review major melanoma treatment studies published prior to 2001.
- To provide a detailed analysis of selected randomized controlled trials (RCTs) conducted between 2001 and 2008.
- To update the understanding of evidence-based melanoma interventions.
Main Methods:
- Systematic review of published literature.
- Analysis of 154 prospective randomized trials from 1975-2000.
- Detailed examination of 52 randomized controlled trials (RCTs) from 2001-2008.
Main Results:
- Significant advancements in melanoma treatment have emerged from extensive research.
- The period 2001-2008 saw 52 new RCTs focusing on malignant melanoma.
- Key studies have refined therapeutic approaches for local, regional, and metastatic disease.
Conclusions:
- Ongoing research through randomized controlled trials is crucial for improving melanoma patient outcomes.
- The reviewed trials highlight progress in minimizing treatment morbidity.
- This review synthesizes recent evidence to guide future clinical practice and research in melanoma.
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:13Randomized Experiments
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
Simple randomization
Simple...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:30Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...